PureTech Health and Mitsubishi Tanabe Pharma took part in the Merck Group-led series A round, which will fund work developing Sonde's voice-based medical monitoring technology.
US-based medical diagnostic technology developer Sonde Health has raised $16m in a series A round led by M Ventures, the corporate venturing unit of pharmaceutical company Merck Group.
The round also included pharmaceutical firms PureTech Health and Mitsubishi Tanabe Pharma, with the latter investing through its MP Healthcare Venture Management subsidiary. Investment firm Neoteny and growth equity fund Canepa Healthcare also participated.
Sonde is developing technology that is designed to enable electronic devices such as smartphones and smart speakers to monitor…
